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WNT11 is a member of the non-canonical Wnt family and 
plays a crucial role in tumor progression. However, the regu-
latory mechanisms underlying WNT11 expression are unclear. 
Tumor necrosis factor-alpha (TNF) is a major inflammatory cyto-
kine produced in the tumor microenvironment and contributes 
to processes associated with tumor progression, such as tumor 
invasion and metastasis. By using site-directed mutagenesis 
and introducing a serial deletion in the 5’-regulatory region of 
WNT11, we observed that TNF activates the early growth 
response 1 (EGR1)-binding sequence (EBS) in the proximal re-
gion of WNT11 and that the transcription factor EGR1 is neces-
sary for the TNF-induced transcription of WNT11. EGR1 
bound directly to the EBSs within the proximal 5'-regulatory 
region of WNT11 and ectopic expression of EGR1 stimulated 
WNT11 promoter activity, whereas the knockdown of EGR1 
expression by RNA interference reduced TNF-induced WNT11 
expression in T47D breast cancer cells. We also observed that 
mitogen-activated protein kinases (MAPK), extracellular signal- 
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 
kinase mediated TNF-induced transcription of WNT11 via 
EGR1. Our results suggest that EGR1 directly targets WNT11 
in response to TNF stimulation in breast cancer cells. [BMB 
Reports 2020; 53(12): 628-633]
INTRODUCTION
Wnt signaling pathways represent a group of highly evolu-
tionarily conserved signal transduction pathways that control 
various physiological responses, including embryonic body 
axis formation, cell fate specification, cell proliferation, and 
cell migration (1). To date, at least 19 Wnt proteins have been 
identified in humans. All Wnt proteins bind and activate the 
Frizzled receptors, which transduce biological signals to the 
appropriate downstream targets (2). Wnt signaling is characte-
rized by the -catenin-dependent canonical pathway and the 
-catenin-independent non-canonical pathway (3). Emerging evi-
dence has implicated canonical and non-canonical Wnt sig-
naling pathways in the development of human cancers, inclu-
ding gastrointestinal cancers, hepatocellular carcinoma, leuke-
mia, melanoma, and breast cancers (4, 5). 
WNT11 plays a crucial role in several morphological pro-
cesses associated with embryogenesis, including anterior-pos-
terior axis elongation through a -catenin-dependent canonical 
or -independent non-canonical pathway (6). WNT11 promotes 
the proliferation and transformation of intestinal epithelial cells 
(7) and the downregulation of its receptor, frizzled-7, apart 
from reducing the survival, invasion, and metastasis of colon 
cancer cells (8). Consistent with the above, WNT11 overexpres-
sion promotes the proliferation and migration of several tumor 
cells, including cervical, breast, prostate, and colon cancer 
cells (9, 10). These results suggest that WNT11 signaling plays 
a crucial role in cell proliferation, invasion, and metastasis 
during carcinogenesis (11). 
The transcription of WNT11 is controlled by multiple factors, 
including lymphoid enhancer-binding factor 1 (LEF1), GATA 
transcription factor (12), and E26 transforming sequence (ETS)- 
related gene (ERG), an ETS family transcription factor involved 
in hematopoiesis (13). In breast cancer cells, Chromatin immuno-
precipitation-linked target site cloning was used to characte-
rize WNT11 as an estrogen receptor target gene (14). 
Tumor necrosis factor-alpha (TNF) is a major inflammatory 
cytokine produced by tumor cells, tumor-associated fibroblasts, 
and infiltrated inflammatory cells in the tumor microenviron-
ment (15). TNF stimulates various inflammatory cytokines 
and chemokines and plays a crucial role in processes asso-
ciated with tumor progression, including tumor invasion and 
metastasis (15-18). However, the role of TNF in the regula-
tion of WNT11 expression remains largely elusive. Owing to 
the role of TNF in tumor progression, we hypothesized that 
TNF may control WNT11 transcription. To evaluate this 
possibility, we isolated the 5’-regulatory region of the WNT11 
gene and evaluated its expression levels in response to TNF 
stimulation in the T47D breast cancer cell line. We observed 
that TNF stimulates WNT11 transcription by activating the 
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Fig. 1. Effect of TNF on WNT11 expression. (A) Basal expression 
of WNT11 mRNA in various cancer cells. (B, C) T47D cells were 
treated with 10 ng/ml TNF for 12 and 24 h. Total RNA was iso-
lated, and the levels of WNT11 mRNA were determined using RT- 
PCR (B) and quantitative real-time PCR (qR-PCR) (C). The levels of 
GAPDH mRNA were determined as an internal control. In (C), the 
0-time mRNA level was set to 1 after adjustment to the GAPDH
levels. Data are presented as mean + S.D. (n = 3). *P = 0.0131; 
***P ＜ 0.001 by Dunnett’s multiple comparisons test. (D) WNT11 
levels were measured by immunoblotting. GAPDH levels were 
determined as an internal control. Band intensities were measured 
using the ImageJ software. After adjustment to the GAPDH levels, 
the 0-time band intensity was set to 1. Data are presented as mean 
+ S.D. (n = 3). *P = 0.0127 (n = 3) by Dunnett’s multiple com-
parisons test. (E) T47D cells were treated with PBS (control) or 
10 ng/ml TNF, and then incubated with antibodies against /- 
tubulin or WNT11 for 2 h, followed by incubation with Alexa 
Fluor 488-conjugated (for /-tubulin; green signal) and Alexa Fluor 
555-conjugated (for WNT11; red signal) secondary antibodies for 
30 min. Nuclear DNA was stained with 1 g/ml Hoechst 33258 for 
10 min (blue staining). White bar size, 50 m. Arrows, WNT11- 
stained spots.
EGR1-binding cis-acting element within the 5’-regulatory 
region of WNT11. We also observed that the three major 
mitogen-activated protein kinases (MAPKs), extracellular signal- 
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 
kinase, mediated TNF-induced WNT11 expression via EGR1 
upregulation.
RESULTS AND DISCUSSION
TNF upregulates WNT11 expression in T47D breast cancer 
cells
We first examined the basal mRNA expression levels of 
WNT11 in various breast and colon cancer cells. MCF-7 and 
T47D breast cancer cells expressed relatively high levels of 
WNT11 mRNA, whereas no expression or low levels of ex-
pression were observed in non-transformed MCF10A breast 
epithelial cells and MDA-MB-231 breast cancer cells (Fig. 1A, 
left panels). Among the different colon cancer cells, the basal 
levels of WNT11 mRNA were relatively high in SW620 and 
HT29 cells, while the same was not observed in SW480 cells 
(Fig. 1A, right panels). We selected and characterized T47D 
cells exhibiting moderate WNT11 expression levels to investi-
gate WNT11 mRNA expression following TNF stimulation. 
An increase in the mRNA levels of WNT11 was detected 
within 12 h, followed by a reduction at 24 h after TNF sti-
mulation, whereas the mRNA levels of the glyceraldehyde 
3-phosphate dehydrogenase gene (GAPDH) remained unaltered, 
as revealed by reverse transcription (RT)-PCR (Fig. 1B) and 
quantitative real-time PCR (qR-PCR) (Fig. 1C). Similar results 
were obtained in MDA-MB-231 breast cancer cells (Supple-
mentary Fig. S1A) and HCT116 colon cancer cells (Supple-
mentary Fig. S2B). TNF-induced elevation of the WNT11 
protein levels was confirmed by immunoblotting in T47D cells 
(Fig. 1D) and MDA-MB-231 cells (Supplementary Fig. S1B). 
Immunofluorescence studies also showed WNT11 antibody- 
staining after TNF stimulation; however, no staining was 
observed in the PBS-treated control (Fig. 1E). These data 
suggest that WNT11 expression can be regulated by TNF in 
T47D breast cancer cells. 
TNF stimulates WNT11 promoter activity by activating the 
EGR1-binding cis-acting element in the proximal promoter 
region of the 5’-regulatory region
To investigate whether TNF stimulates WNT11 transcription, 
a fragment of the 5’-regulatory region spanning nucleotides 
−997 to +74 was isolated, and the effect exerted by TNF on 
the activation of the WNT11 promoter was assessed. We ob-
served that TNF significantly enhanced the promoter-reporter 
activity (Fig. 2A), suggesting that TNF enhances WNT11 
expression at the transcriptional level. To delineate the pro-
moter region that is responsible for TNF-induced WNT11 
promoter activation, we designed a series of deletion constructs 
and mapped the TNF response region. Upon TNF stimu-
lation, the shortest reporter construct (−53/+74) continued to 
exhibit induction (Fig. 2A), suggesting that the TNF-inducible 
region of the WNT11 promoter is located between nucleotides 
−53 and +74. 
To identify the functional cis-acting element responsible for 
TNF-induced WNT11 gene transcription, we analyzed the 
transcription factor regulatory sequences between nucleotides 
−53 and +74 using a web-based MatInspector transcription 
factor search tool (http://www.genomatix.de/). We found two 
putative early growth response protein 1 (EGR1)-binding se-
quences (EBSs) spanning nucleotides −22 to +18 (named 
EBS-1, −22 to −4, and EBS-2, −1 to +18) (Fig. 2B). EGR1, 
also known as zinc finger protein 225 (Zif268) or nerve growth 
factor-induced clone A (NGFI-A), is a Cys2His2-type zinc finger 
protein that exhibits Fos-like induction kinetics in response to 
various mitogenic stimuli and DNA damage signals (19). The 
target genes of EGR1 are associated with multiple physio-
logical responses, including cell proliferation, differentiation, 
apoptosis, and inflammation, in a variety of cell types (19, 20). 
However, the role of EGR1 in WNT11 transcription remains 
elusive. 
To assess the functional role of these putative EBSs in 
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Fig. 2. Role of EGR1 in TNF-induced WNT11 expression. (A) 
HEK293 cells were transiently transfected with 0.2 g of a series 
of 5’-deletion constructs. After treating with vehicle (PBS) or 10 ng/ 
ml TNF, luciferase activities were measured. (B) Sequence elements 
of EBS between −22 to +18 in the −53/+73 construct (top sub-
figure). HEK293 cells were transiently transfected with site-specific 
mutants derived from the −53/+74 construct. After treatment with 
the vehicle (PBS) or with 10 ng/ml TNF, luciferase activities 
were measured. EBS, EGR1-binding sequence; mtEBS, mutation of 
EBS. Asterisk (*) indicates a mutation site. Luciferase activity data are 
presented as mean + S.D. (n = 3). ***P ＜ 0.001 by Sidak’s multi-
ple comparisons test. (C) T47D cells were treated with 10 ng/ml
TNF for 0, 3, and 6 h. After preparing the nucleus-enriched frac-
tions, EGR1 levels were measured by immunoblotting. (D) HEK293 
cells were transiently cotransfected with 0.2 g of the −150/+74 
construct and EGR1 expression plasmid (pcDNA3.1/Egr1). Forty-eight 
hours later, the cells were harvested, and luciferase activities were 
measured. Data are presented as mean + S.D. (n = 3). The tran-
sfected EGR1 levels were confirmed by immunoblotting. (E and F) 
T47D transfectants stably expressing control scrambled shRNA 
(shCT) or EGR1 shRNA (shEgr1) were treated with 10 ng/ml TNF
for 0.5 or 12 h. Expression levels of the EGR1 and WNT11 mRNAs 
were measured by RT-PCR (E), and WNT11 mRNA levels were 
quantitated by quantitative real-time PCR (qR-PCR) (F). qR-PCR data 
are presented as mean + S.D. (n = 3). NS, not significant; ***P 
＜ 0.001 by Sidak’s multiple comparisons test.
Fig. 3. Binding of EGR1 to putative EBS motifs of WNT11. (A, B) 
EBS-1 (A) and EBS-2 (B) probes were incubated with lysates of 
Sf21 cells expressing EGR1 (Sf21/EGR1) or with the wild-type (Sf21/ 
WT) in the presence or absence of an unlabeled probe (cold compe-
titor). Samples were separated by non-denaturing 6% acrylamide gel 
electrophoresis and visualized using streptavidin-conjugated horse-
radish peroxidase. (C and D) T47D cells were treated with 10 ng/ml
TNF for 1 h or were left untreated. Nuclear extracts were prepared 
and incubated with biotinylated EBS-1 (C) or EBS-2 (D), followed 
by the addition of streptavidin-conjugated agarose beads. After 1 h, 
the agarose beads were washed and boiled for 5 min with 2 ×
Laemmli sample buffer. Immunoblotting was performed using anti- 
EGR1 or anti-PCNA antibodies. Input, an aliquot of the nuclear 
extract; DAPA, DNA-affinity precipitation assay.
TNF-induced WNT11 transcription, we introduced site-directed 
mutations into the EBSs. Damage to the EBS-1 (mtEBS-1) or 
EBS-2 (mtEBS-2) motifs in the pWnt11-Luc(−53/+74) signifi-
cantly reduced TNF-induced reporter activity compared to 
that in the wild-type (WT) construct (Fig. 2B, bottom graph). 
Damage to both EBS-1 and EBS-2 sites resulted in an almost 
complete loss of TNF inducibility. 
TNF induces EGR1 expression in various cell types (21-24). 
Consistently, we observed that EGR1 expression increased in a 
time-dependent manner upon TNF- stimulation (Fig. 2C). To 
determine whether EGR1 transactivates WNT11, we transfected 
the −150/+74 construct into T47D cells, along with an expres-
sion plasmid for EGR1. Exogenous overexpression of EGR1 
enhanced the WNT11 promoter-reporter activity in a plasmid 
concentration-dependent manner (Fig. 2D). These results sug-
gest that EGR1 can transactivate WNT11 in T47D cells. 
To further investigate the role of EGR1 in TNF-induced 
WNT11 transcription, we established T47D transfectants expres-
sing lentiviral shRNA against EGR1 (T47D/shEgr1) and a 
scrambled control (T47D/shCT). The stable knockdown of 
basal and TNF-induced expression of EGR1 mRNA was 
confirmed by RT-PCR after TNF treatment (Fig. 2E, top 
panels). The ability of TNF to induce the mRNA expression 
of WNT11 was substantially attenuated when EGR1 expression 
in T47D/shEgr1 was reduced compared to that in T47D/shCT 
cells (Fig. 2E, bottom panels). qR-PCR analysis revealed that 
TNF elevated WNT11 mRNA expression by 3.17 ± 0.306- 
fold in T47D/shCT cells, while it reduced WNT11 mRNA 
expression by 0.600 ± 0.100-fold in T47D/shEgr1 cells (Fig. 
2F). These results suggest that the EBS motifs in the promoter 
region are necessary for the TNF-induced transcription of 
WNT11 .
EGR1 binds to the EBS motif and transactivates WNT11 
transcription
To determine whether the EBS motif can serve as a binding 
site for EGR1, we performed the non-radioactive electrophoretic 
mobility shift assay (EMSA) using Sf21 insect cell lysates 
overexpressing EGR1 (Sf21/Egr1) and biotinylated EBS oligo-
nucleotide probes. Biotinylated consensus EBS oligonucleo-
tides were used as a positive control. We observed that the 
biotinylated EBS-1 (Fig. 3A) and EBS-2 (Fig. 3B) probes formed 
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Fig. 4. Role of MAPKs in TNF-induced WNT11 expression. (A) 
T47D cells were treated with 10 ng/ml TNF for various dura-
tions (0-1200 min). Immunoblotting was performed using a phos-
pho-specific antibody against ERK1/2 (Thr202/Tyr204), JNK1/2 (Thr183/ 
Tyr185), or p38 kinase (Thr180/Tyr182). GAPDH levels were deter-
mined as an internal control. (B, C) T47D cells were pretreated 
with U0126 (10 M), SB203580 (20 M), or SP600125 (20 M) 
for 30 min and then stimulated with 10 ng/ml TNF. After 1 and 
12 h, the levels of EGR1 (B) and WNT11 mRNAs (C) were mea-
sured by immunoblotting and RT-PCR, respectively. The band in-
tensities were measured relative to the GAPDH levels using the 
ImageJ software. Bars represent the mean ± S.D. (n = 3). *P = 
0.0149; **P = 0.0017; ***P ＜ 0.001 by Dunnett’s multiple compa-
rison test. 
DNA-protein complexes. These complexes competed with a 
molar excess of an unlabeled probe. These data suggest that 
EGR1 binds specifically to the EBS motifs within the proximal 
WNT11 promoter region. 
To further corroborate the binding of EGR1 to the EBS motifs 
in WNT11, we adopted an alternative approach using the 
DNA-affinity precipitation assay (DAPA). Biotinylated EBS-1 
and EBS-2 oligonucleotides were incubated with nuclear ex-
tracts from T47D cells. Upon TNF stimulation, the levels of 
EGR1 and nuclear protein PCNA increased in the whole 
nuclear extract (input) (Fig. 3C and D; bottom panels). After 
pull-down with streptavidin-agarose beads, oligonucleotide-bin-
ding proteins were eluted and immunoblotted with an 
anti-EGR1 or anti-PCNA antibody. We observed that while 
EBS-1 and EBS-2 bound EGR1 in response to TNF stimu-
lation, they did not bind PCNA (Fig. 3C and D; top panels). 
These data suggest that the proximal EBS sites located between 
nucleotides −22 and +18 in the WNT11 promoter region 
bind EGR1; however, they do not exhibit any off-target effect. 
MAPKs mediate TNF-induced WNT11 expression via EGR1 
upregulation
Transcription factor ETS like-1 protein (ELK1) and serum res-
ponse factor (SRF) complex transactivate the serum response 
element (SRE) in the 5’-regulatory region of the EGR1 gene. 
MAPK pathways control EGR1 expression via phosphorylation 
of ELK-1 in response to TNF stimulation in several cell types 
(21, 25, 26). To determine which MAPK pathways are 
responsible for EGR1-mediated WNT11 expression, we vali-
dated the active status of TNF-induced MAPKs in serum- 
starved T47D cells. The phosphorylation levels of ERK1/2 at 
Thr-202/Tyr-204, JNK1/2 at Thr-183/Tyr-185, and p38 kinase 
at Thr-180/Tyr-182 increased within 30 min in response to 
TNF stimulation (Fig. 4A). Pretreatment with MAPK inhibi-
tors, including the MAPK kinase (MEK) inhibitor U0126, JNK 
inhibitor SP600125, and p38 kinase inhibitor SB203580, 
substantially abrogated the TNF-induced accumulation of 
EGR1 proteins (Fig. 4B). Consistent with EGR1 expression 
results, all MAPK inhibitors significantly reduced TNF-in-
duced WNT11 expression; in particular, U0126 and SP600125 
showed a strong inhibitory effect compared to SB203580 (Fig. 
4C). These data suggest that all three major MAPK pathways 
contribute to EGR1-mediated WNT11 expression in response 
to TNF exposure in T47D breast cancer cells.
The current study identified the role of EGR1 in TNF- 
induced WNT11 expression in T47D human breast cancer 
cells. In response to TNF stimulation, EGR1 directly bound to 
the EBS in the WNT11 promoter region and stimulated 
WNT11 transcription. All three major MAPKs, ERK, JNK, and 
p38 kinases, were involved in TNF-induced EGR1 upregu-
lation. We conclude that WNT11 is a direct target of the EGR1 
in response to TNF stimulation, further expending our 
understanding of the regulatory mechanism of WNT11 expres-
sion in the tumor microenvironment. As WNT11 activates 
cancer cell motility and metastasis (27) and reduction of 
WNT11 expression decreases the ability of breast cancer cells 
to migrate (9), EGR1-regulated WNT11 expression can be a 
promising therapeutic target for suppressing metastasis of 
breast cancer. Further in vivo studies are warranted to verify 
the clinical relevance of targeting the TNF-EGR1-WNT11 axis 
to prevent tumor metastasis in breast cancer.
MATERIALS AND METHODS
Cell and reagents
Detailed cells and reagents used in this study were described 
in Supplementary materials. 
Reverse transcription-PCR (RT-PCR) 
Total RNA was isolated using a TRIzol RNA extraction kit 
(Invitrogen). First-strand cDNA was synthesized using an iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The PCR 
conditions were as follows: hold for 5 min at 94oC, followed 
by 30 cycles of denaturation at 94oC (30 s), annealing at 55oC 
(30 s), and elongation at 72oC (1 min). The gene-specific PCR 
primers were as follows: WNT11 forward, 5’ GAT CCC AAG 
CCA ATA AAC TGA TGC GTC T-3’; WNT11 reverse, 5’-GTC 
TTG TTG CAC TGC CTG TCT TGT GTC C-3’; GAPDH 
forward, 5’ CCAAGGAGTAAGAAACCCTGGAC-3’; GAPDH 
reverse, 5’-GGGCCGAGT TGGGATAGG G-3’. The amplified 
products were electrophoresed in 1% agarose gel. 
Immunoblotting
Immunoblot analysis was performed as described previously 
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(21). Detailed experimental methods were described in 
Supplementary materials. 
Immunofluorescence 
T47D cells cultured on coverslips were either treated with the 
vehicle (PBS) or 10 ng/ml TNF for 18 h, followed by fixation, 
permeabilization, and incubation with primary antibodies 
against WNT11 and /-tubulin (for counterstaining). After 2 
h, the cells were incubated for 30 min with secondary 
antibodies conjugated with Alexa Fluor 555 (for /-tubulin; 
red signal) and Alexa Fluor 488 (for WNT11, green signal). 
Nuclear DNA was stained using 1 g/ml Hoechst 33258 for an 
additional 10 min (blue signal). Fluorescently-stained cells 
were examined under an EVOS FL fluorescence microscope 
(Advanced Microscopy Group, Bothell, WA, USA). 
Construction and mutagenesis of human WNT11 
promoter-reporter constructs
Detailed experimental methods for the generation of the 
human WNT11 promoter-reporter constructs and primer sequen-
ces were described in Supplementary materials. 
WNT11 promoter-reporter assay
HEK293T cells cultured in 12-well plates were transfected with 
0.2 g WNT11 promoter constructs using Lipofectamine 2000 
(Invitrogen), according to the manufacturer’s instructions. 
Detailed experimental methods for promoter-reporter assay 
were described in Supplementary materials. 
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a LightShift Chemiluminescence 
EMSA kit, according to the manufacturer’s instructions (Thermo-
Fisher Scientific, Waltham, MA, USA). Biotin-labeled deoxyo-
ligonucleotide probes specific for EBS-1 (5’-CCT TAA CCC 
GCC GCC TCC GCT CTC C-biotin-3’), EBS-2 (5’-AGG CGG 
CGC GCG GGC GGG GGA GGC G-biotin-3’), and the 
consensus EBS sequence (5’-GGA TCC AGC GGG GGC GAG 
CGG GGG CGA-biotin-3’) were obtained from Macrogen. For 
the competition assay, 1 and 2.5 pmole of the unlabeled EBS-1 
and EBS-2 probes (competitor) were added, respectively. DNA- 
protein complexes were electrophoresed in non-denaturing 
6% polyacrylamide gels and visualized using an ECL chemilu-
minescence system (GE Healthcare Life Science).
DNA-affinity precipitation assay (DAPA)
DAPA was performed as reported previously (28). Briefly, 
nuclear extracts (35 g) were incubated with 500 pmol of 
biotinylated EBS-1 (5ʹ-biotin-CCT TAA CCC GCC GCC TCC 
GCT CTC C-3’) or EBS-2 (5ʹ-biotin-AGG CGG CGC GCG GGC 
GGG GGA GGC G-3’) oligonucleotide and streptavidin-con-
jugated agarose beads (Invitrogen) for 1 h, as described pre-
viously (29). After washing thrice with PBS, the pellets were 
boiled with 2 × Laemmli sample buffer and immunoblot analy-
sis was performed using antibodies against EGR1 or PCNA 
(off-target control).
EGR1 silencing using RNA interference
T47D cells were incubated with lentiviral shRNA (TRCN_ 
0000273850; MISSIONⓇ shRNA; Sigma-Aldrich) targeting EGR1, 
according to the manufacturer’s instructions. After 2 wk, the 
silencing of EGR1 expression was determined by immuno-
blotting. 
Statistical analysis
Statistical significance of results was determined using 
one-way analysis of variance (ANOVA), followed by Sidak’s 
multiple comparisons test or Dunnett’s multiple comparisons 
test using the GraphPad Prism version 8.3.1 software (Graph-
Pad Software Inc., La Jolla, CA, USA). A P-value ＜ 0.05 was 
considered statistically significant.
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